Vanguard Capital Management’s Apimeds Pharmaceuticals US APUS Stock Holding History
Bought
Maintained
Sold
Other funds holding APUS
Vanguard Capital Management's APUS Position: Q3 2026 in Review
Vanguard Capital Management reduced its Apimeds Pharmaceuticals US (APUS) stake by 19% in Q3 2026, selling an estimated $5.82K and leaving 5,162 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3961.
Vanguard Capital Management first reported a position in APUS in Q1 2026 and has held it in 3 quarters since. The position peaked at $172K in Q1 2026. 9 funds tracked by Wall St. Rank hold APUS as of Q3 2026.
- Vanguard Capital Management held 5,162 shares of Apimeds Pharmaceuticals US worth $25.8K as of Q3 2026.
- Vanguard Capital Management sold 1,203 Apimeds Pharmaceuticals US shares in Q3 2026, an estimated $5.82K.
- Apimeds Pharmaceuticals US made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3961 holding.
- Vanguard Capital Management first reported a position in Apimeds Pharmaceuticals US in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Apimeds Pharmaceuticals US position peaked at $172K in Q1 2026.
- 9 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.